Oncocyte Corporation - Common Shares, No Par Value (OCX)

CUSIP: 68235C107

Q1 2017 13F Holders as of 31 Mar 2017

Holder snapshot 6 signals
Share change
+732,490
SEC-reported price per share
$5.94
Indexed holders
25
Value change
+$4,356,561
Number of buys
15
Number of sells
4
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
28,495,649

Security key

68235C107

Report period

Q1 2017

Indexed institutions

25

Top holders

10

Ownership snapshot

Top reported holders of OCX - Oncocyte Corporation - Common Shares, No Par Value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
BROADWOOD CAPITAL INC
Disclosed value leader
BROADWOOD CAPITAL INC
Comparable rows
0/15
Latest evidence
31 Dec 2016
13F Highest disclosed value: $18,553,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

BROADWOOD CAPITAL INC has the largest disclosed position value at $18.55M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BROADWOOD CAPITAL INC's linked filing trail.
Disclosed position value Top 5
BROADWOOD CAPITAL INC $18.55M
BRIDGEWAY CAPITAL MANAGEMENT, LLC $705K
VANGUARD GROUP INC $683K
Manatuck Hill Partners, LLC $592K
BlackRock Institutional Trust Com... $488K

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
BROADWOOD CAPITAL INC
13F
Company
13F
—
denominator unverified
$18,553,000
2,631,680 shares
— 31 Dec 2016
BRIDGEWAY CAPITAL MANAGEMENT, LLC
13F
Company
13F
—
denominator unverified
$705,000
100,000 shares
— 31 Dec 2016
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$683,000
96,878 shares
— 31 Dec 2016
Manatuck Hill Partners, LLC
13F
Company
13F
—
denominator unverified
$592,000
83,958 shares
— 31 Dec 2016
BlackRock Institutional Trust Company, N.A.
13F
Company
13F
—
denominator unverified
$488,000
69,217 shares
— 31 Dec 2016
Artal Group S.A.
13F
Company
13F
—
denominator unverified
$452,000
64,102 shares
— 31 Dec 2016
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2017

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
25
Shares
3,775,245
Indexed holders
25
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q1 2017 vs Q4 2016 Across Filers

Q4 2016 indexed holders
24
Q1 2017 indexed holders
25
Indexed holder difference
1
Investor Q4 2016 Shares Q1 2017 Shares Share Diff Share Chg % Q4 2016 value Q1 2017 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .